Yamato Motooka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yamato Motooka has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Makoto Suzuki
Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
3 shared publications- Makoto Suzuki
Department of Pathology Shizuoka General Hospital Shizuoka Japan
3 shared publications - Koei Ikeda
Department of Thoracic Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan
2 shared publications Kosuke Fujino
Division of Thoracic Surgery, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada; Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
2 shared publicationsShinji Kudoh
Department of Pathology and Experimental Medicine, Kumamoto University Graduate School of Medical Sciences
2 shared publications- Takaaki Ito
Kumamoto Health Science University Kumamoto Japan
2 shared publications
Latest Publications
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S528-S529
EP07.02-10 Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer
- 31 October 2023
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 18 (11) , S528-S529
EP07.02-10 Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer
- Open Access
- 29 October 2021
- Published by Japan Society of Histochemistry & Cytochemistry in ACTA HISTOCHEMICA ET CYTOCHEMICA
- Vol. 54 (5) , 143-153
ZMYM3 May Promote Cell Proliferation in Small Cell Lung Carcinoma
Zinc finger, myeloproliferative, and mental retardation-type containing 3 (ZMYM3) is a highly conserved protein among vertebrates. Although it promotes DNA repair and moderate histone acetylation, the other functions of ZMYM3 remain unclear. We herein examined the physiological functions of ZMYM3 in human lung cancer using a ZMYM3-knockdown small cell lung cancer (SCLC) cell line. ZMYM3-knockdown SCLC cells grew slowly and the Ki-67 labeling index was lower in ZMYM3-knockdown cells than in mock cells. The subcutaneous tumors that formed after xenotransplantation into immunodeficient mice were slightly smaller in the ZMYM3-knockdown group than in the mock group. Furthermore, public RNA-sequencing data analyses showed similar RNA profiles between ZMYM3 and some cell proliferation markers. These results indicate that ZMYM3 promotes cell proliferation in human lung carcinomas, particularly SCLC.
- 29 October 2021
- Published by Japan Society of Histochemistry & Cytochemistry in ACTA HISTOCHEMICA ET CYTOCHEMICA
- Vol. 54 (5) , 143-153
Open AccessZMYM3 May Promote Cell Proliferation in Small Cell Lung Carcinoma
Zinc finger, myeloproliferative, and mental retardation-type containing 3 (ZMYM3) is a highly conserved protein among vertebrates. Although it promotes DNA repair and moderate histone acetylation, the other functions of ZMYM3 remain unclear. We herein examined the physiological functions of ZMYM3 in human lung cancer using a ZMYM3-knockdown small cell lung cancer (SCLC) cell line. ZMYM3-knockdown SCLC cells grew slowly and the Ki-67 labeling index was lower in ZMYM3-knockdown cells than in mock cells. The subcutaneous tumors that formed after xenotransplantation into immunodeficient mice were slightly smaller in the ZMYM3-knockdown group than in the mock group. Furthermore, public RNA-sequencing data analyses showed similar RNA profiles between ZMYM3 and some cell proliferation markers. These results indicate that ZMYM3 promotes cell proliferation in human lung carcinomas, particularly SCLC.
- Open Access
- 3 February 2021
- Published by Springer Nature in Surgical Case Reports
- Vol. 7 (1) , 1-5
Specific techniques for right sleeve lower lobectomy: four case reports
Background Right sleeve lower lobectomy is rarely performed because pulmonary function of the middle lobe is not spared to the extent of the other lobes and achieving a proper bronchial anastomosis is technically more difficult than other sleeve lobectomies. Case presentation We performed four right sleeve lower lobectomies and had good clinical outcomes using specific technical options, such as telescope anastomosing, pericardiotomy, interlobar dissection between the upper and middle lobes, and angioplasty of the lower pulmonary artery, if needed. Conclusions The cases presented herein demonstrated that a right sleeve lower lobectomy is one option by which to preserve the middle lobe using specific techniques and is thus recommended in select patients.
- 3 February 2021
- Published by Springer Nature in Surgical Case Reports
- Vol. 7 (1) , 1-5
Open AccessSpecific techniques for right sleeve lower lobectomy: four case reports
Background Right sleeve lower lobectomy is rarely performed because pulmonary function of the middle lobe is not spared to the extent of the other lobes and achieving a proper bronchial anastomosis is technically more difficult than other sleeve lobectomies. Case presentation We performed four right sleeve lower lobectomies and had good clinical outcomes using specific technical options, such as telescope anastomosing, pericardiotomy, interlobar dissection between the upper and middle lobes, and angioplasty of the lower pulmonary artery, if needed. Conclusions The cases presented herein demonstrated that a right sleeve lower lobectomy is one option by which to preserve the middle lobe using specific techniques and is thus recommended in select patients.
- 1 May 2019
- Published by Elsevier in Lung Cancer
- Vol. 131, 104-111
Significance of Tsukushi in lung cancer
- 1 May 2019
- Published by Elsevier in Lung Cancer
- Vol. 131, 104-111
Significance of Tsukushi in lung cancer
- 1 September 2016
- Vol. 69 (10) , 847-51
[Chronic Progressive Pulmonary Aspergillosis after Surgery for Lung Cancer].
Case 1:A 62-year-old man underwent right S9+10 segmentectomy for non-small cell lung cancer. Three years later, pleural thickening appeared in the apex, and gradually developed cystic change. Case 2:A 64-year-old man underwent left upper lobectomy for non-small cell lung cancer. One year after surgery, chest computed tomography (CT) showed cysts in the apex of the lower lobe. The cysts expanded slowly with consolidation. Both cases were diagnosed as chronic progressive pulmonary aspergillosis. Although anti-fungal drugs were administered in both cases, case 1 died of the disease. Chronic progressive pulmonary aspergillosis is a rare late postoperative complication;when CT shows progressive cysts with consolidation in the apex area of the residual lung, frequent check-ups are needed.
- 1 September 2016
- Vol. 69 (10) , 847-51
[Chronic Progressive Pulmonary Aspergillosis after Surgery for Lung Cancer].
Case 1:A 62-year-old man underwent right S9+10 segmentectomy for non-small cell lung cancer. Three years later, pleural thickening appeared in the apex, and gradually developed cystic change. Case 2:A 64-year-old man underwent left upper lobectomy for non-small cell lung cancer. One year after surgery, chest computed tomography (CT) showed cysts in the apex of the lower lobe. The cysts expanded slowly with consolidation. Both cases were diagnosed as chronic progressive pulmonary aspergillosis. Although anti-fungal drugs were administered in both cases, case 1 died of the disease. Chronic progressive pulmonary aspergillosis is a rare late postoperative complication;when CT shows progressive cysts with consolidation in the apex area of the residual lung, frequent check-ups are needed.
- Open Access
- 8 January 2016
- Published by Springer Nature in Surgical Case Reports
- Vol. 2 (1) , 1-4
Pulmonary hepatoid adenocarcinoma: report of a case
Hepatoid adenocarcinoma (HAC) is a rare neoplasm with aberrant hepatocellular differentiation. HAC occurs in extrahepatic organs such as the gastrointestinal tract, testes, ovaries, and lungs and frequently produces alpha-fetoprotein. A 69-year-old patient was diagnosed clinically with T2aN0M0, stage IB, non-small cell lung carcinoma. Because the tumor showed tight adhesion to the chest wall, we performed left upper lobectomy, combined resection of the 3rd and 4th ribs, and lymph node dissection. Pathological examination confirmed the diagnosis of HAC of the lung (pathological T2aN0M0, stage IB), and four courses of cisplatin and gemcitabine were administered as adjuvant chemotherapy. Genetic analysis of the epidermal growth factor receptor showed wild type. Preoperative serum alpha-fetoprotein level, a useful marker of disease progression, was elevated to 4497 ng/ml, decreasing within the normal range by about 3 months postoperatively. The patient remains alive without recurrence as of 51 months after surgery.
- 8 January 2016
- Published by Springer Nature in Surgical Case Reports
- Vol. 2 (1) , 1-4
Open AccessPulmonary hepatoid adenocarcinoma: report of a case
Hepatoid adenocarcinoma (HAC) is a rare neoplasm with aberrant hepatocellular differentiation. HAC occurs in extrahepatic organs such as the gastrointestinal tract, testes, ovaries, and lungs and frequently produces alpha-fetoprotein. A 69-year-old patient was diagnosed clinically with T2aN0M0, stage IB, non-small cell lung carcinoma. Because the tumor showed tight adhesion to the chest wall, we performed left upper lobectomy, combined resection of the 3rd and 4th ribs, and lymph node dissection. Pathological examination confirmed the diagnosis of HAC of the lung (pathological T2aN0M0, stage IB), and four courses of cisplatin and gemcitabine were administered as adjuvant chemotherapy. Genetic analysis of the epidermal growth factor receptor showed wild type. Preoperative serum alpha-fetoprotein level, a useful marker of disease progression, was elevated to 4497 ng/ml, decreasing within the normal range by about 3 months postoperatively. The patient remains alive without recurrence as of 51 months after surgery.